Chemotherapy and Drug Information

Risk of Bladder Recurrence Reduced With Chemotherapy Flush After Tumor Resection

Risk of Bladder Recurrence Reduced With Chemotherapy Flush After Tumor Resection

Flushing the bladder with a chemotherapeutic agent after tumor resection significantly reduced recurrence rates of bladder cancer.

New Safety Concerns in One-Third of FDA-Approved Drugs 3 Years After Approval

New Safety Concerns in One-Third of FDA-Approved Drugs 3 Years After Approval

New safety issues are detected in almost one-third of drugs approved by the US FDA in the first 3 years after approval.

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

No Improvement in KRAS-Mutation Lung Cancer With MEK Inhibitor Plus Chemotherapy

A combination treatment of mitogen-activated protein kinase MEK inhibitor and chemotherapy did not improve progression-free survival in patients with advanced lung cancer caused by a KRAS gene mutation.

Significant Reductions in CLABSIs Achieved With Daily Chlorhexidine Bathing in Oncology Population

Significant Reductions in CLABSIs Achieved With Daily Chlorhexidine Bathing in Oncology Population

Daily CHG bathing can safely reduce CLABSIs in oncology patients with central lines, with small variations in efficacy of the practice due to differences in patient population, work processes, and team engagement.

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

Cisplatin Plus Standard-of-Care Regimen Reduced Tumors in Advanced Pancreatic Cancer

Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.

Research Shows Temozolomide Has Potential to Increase Depression

Research Shows Temozolomide Has Potential to Increase Depression

Temozolomide, an antimitotic chemotherapy used to treat brain cancer, demonstrated the potential to increase depression in a mouse model.

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

Standardized Assessment Tool Prevents Chemotherapy-Induced Neurotoxicity

Standardized tool improved efficiency and thoroughness of patient assessment and documentation of neurotoxicity caused by high-dose cytarabine.

Education and Coaching Are Necessary to Treat Oropharyngeal Cancers After Chemoradiotherapy

Education and Coaching Are Necessary to Treat Oropharyngeal Cancers After Chemoradiotherapy

A literature review noted improvements in quality of life after patients were coached and educated following radiotherapy for HPV-associated oropharyngeal cancers.

New Closed System Drug Transfer Device Can Reduce Nurse Exposure to Antineoplastic Hazardous Drugs

New Closed System Drug Transfer Device Can Reduce Nurse Exposure to Antineoplastic Hazardous Drugs

A new CSTD significantly reduced surface contamination during a simulated antineoplastic hazardous drug administration when compared to baseline.

Standardized Process for Assessing Chemotherapy Appointments Improves Patient Wait Times

Standardized Process for Assessing Chemotherapy Appointments Improves Patient Wait Times

Prior assessment of patients and review of infusion orders by an interprofessional ACE team can significantly reduce patient wait times, prevent same-day inefficiencies, and reduce wasted chemotherapy doses.

Stat Consult Slideshows

Fluorouracil (5-FU)

This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.

Netupitant/Palonosetron (Akynzeo)

This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.

Bevacizumab (Avastin) - cervical cancer

This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.

To view all content in our Stat Consult section, please click here.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs